Jens Kleinehr

Mr. Jens Kleinehr

Institute of Virology Muenster (IVM) of the Westfaelische Wilhelms-University Muenster
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 October 2021 in Viruses
Verified
Journal Article
Open access
PDF file
JKJens Kleinehr
Jens Kleinehr
JWJanine J. Wilden
Janine J. Wilden
YBYvonne Börgeling
Yvonne Börgeling
SLStephan Ludwig
Stephan Ludwig
EHEike R. Hrincius
Eike R. Hrincius
Respiratory viruses are known to be the most frequent causative mediators of lung infections in humans, bearing significant impact on the host cell signaling machinery due to their host-dependency for efficient replication. Certain cellular functions are actively induced by respiratory viruses for their own benefit. This includes metabolic pathways such as glycolysis, fatty acid synthesis (FAS) and the tricarboxylic acid (TCA) cycle, among others, which are modified during viral infections. Here, we summarize the current knowledge of metabolic pathway modifications mediated by the acute respiratory viruses respiratory syncytial virus (RSV), rhinovirus (RV), influenza virus (IV), parainfluenza virus (PIV), coronavirus (CoV) and adenovirus (AdV), and highlight potential targets and compounds for therapeutic approaches.

13 July 2023 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
JKJens Kleinehr
Jens Kleinehr
Michael SchöfbänkerMichael Schöfbänker
Michael Schöfbänker
KDKatharina Daniel
Katharina Daniel
FGFranziska Günl
Franziska Günl
Fakry F. MohamedFakry F. Mohamed
Fakry F. Mohamed
EHEike R. Hrincius
Eike R. Hrincius
Influenza A virus (IAV), like any other virus, provokes considerable modifications of its host cell’s metabolism. This includes a substantial increase in the uptake as well as the metabolization of glucose. Although it is known for quite some time that suppression of glucose metabolism restricts virus replication, the exact molecular impact on the viral life cycle remained enigmatic so far. Using 2-deoxy-d-glucose (2-DG) we examined how well inhibition of glycolysis is tolerated by host cells and which step of the IAV life cycle is affected. We observed that effects induced by 2-DG are reversible and that cells can cope with relatively high concentrations of the inhibitor by compensating the loss of glycolytic activity by upregulating other metabolic pathways. Moreover, mass spectrometry data provided information on various metabolic modifications induced by either the virus or agents interfering with glycolysis. In the presence of 2-DG viral titers were significantly reduced in a dose-dependent manner. The supplementation of direct or indirect glycolysis metabolites led to a partial or almost complete reversion of the inhibitory effect of 2-DG on viral growth and demonstrated that indeed the inhibition of glycolysis and not of N-linked glycosylation was responsible for the observed phenotype. Importantly, we could show via conventional and strand-specific qPCR that the treatment with 2-DG led to a prolonged phase of viral mRNA synthesis while the accumulation of genomic vRNA was strongly reduced. At the same time, minigenome assays showed no signs of a general reduction of replicative capacity of the viral polymerase. Therefore, our data suggest that the significant reduction in IAV replication by glycolytic interference occurs mainly due to an impairment of the dynamic regulation of the viral polymerase which conveys the transition of the enzyme’s function from transcription to replication.

2 March 2021 in Cellular Microbiology
Verified
Journal Article
Open access
PDF file
GTGiao Vu Quynh Tran
Giao Vu Quynh Tran
JKJens Kleinehr
Jens Kleinehr
HPHannah Franziska Preugschas
Hannah Franziska Preugschas
DADarisuren Anhlan
Darisuren Anhlan
Fakry F. MohamedFakry F. Mohamed
Fakry F. Mohamed
EHEike Roman Hrincius
Eike Roman Hrincius
Nonsense‐mediated mRNA decay (NMD) was identified as a process to degrade flawed cellular messenger RNA (mRNA). Within the last decades it was also shown that NMD carries virus‐restricting capacities and thus could be considered a part of the cellular antiviral system. As this was shown to affect primarily positive‐sense single stranded RNA ((+)ssRNA) viruses there is only scarce knowledge if this also applies to negative‐sense single stranded RNA ((−)ssRNA) viruses. Influenza A viruses (IAVs) harbour a segmented (−)ssRNA genome. During their replication IAVs produce numerous RNA transcripts and simultaneously impair cellular transcription and translation. The viral mRNAs hold several molecular patterns which can elicit NMD and in turn would lead to their degradation. This, in consequence, may mitigate viral propagation. Thus, we examined if a knockdown or a pharmacological inhibition of NMD key components may influence IAV replication. Additionally, we performed similar experiments with respiratory syncytial virus (RSV), another (−)ssRNA virus, but with a non‐segmented genome. Although it seemed that a knockdown of up‐frameshift protein 1 (UPF1), the central NMD factor, slightly increased viral mRNA and protein levels, no significant alteration of viral replication could be observed, implying that the NMD machinery may not have restricting capacities against (−)ssRNA viruses.

9 November 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
JKJens Kleinehr
Jens Kleinehr
KDKatharina Daniel
Katharina Daniel
FGFranziska Günl
Franziska Günl
JJJosua Janowski
Josua Janowski
LBLinda Brunotte
Linda Brunotte
EHEike R. Hrincius
Eike R. Hrincius
Influenza A virus (IAV), like any other virus, provokes considerable modifications of its host cell’s metabolism. This includes a substantial increase in the uptake as well as the metabolization of glucose. Although it is known for quite some time that suppression of glucose metabolism restricts virus replication, the exact molecular impact on the viral life cycle remained enigmatic so far. Using 2-deoxy-D-glucose (2-DG) we examined how well inhibition of glycolysis is tolerated by host cells and which step of the IAV life cycle is affected. We observed that effects induced by 2-DG are reversible and that cells can cope with relatively high concentrations of the inhibitor by compensating the loss of glycolytic activity by upregulating other metabolic pathways. Moreover, mass spectrometry data provided information on various metabolic modifications induced by either the virus or agents interfering with glycolysis. In the presence of 2-DG viral titers were significantly reduced in a dose-dependent manner. The supplementation of direct or indirect glycolysis metabolites led to a partial or almost complete reversion of the inhibitory effect of 2-DG on viral growth and demonstrated that indeed the inhibition of glycolysis and not of N -linked glycosylation was responsible for the observed phenotype. Importantly, we could show via conventional and strand-specific qPCR that the treatment with 2-DG led to a prolonged phase of viral mRNA synthesis while the accumulation of genomic vRNA was strongly reduced. At the same time, minigenome assays showed no signs of a general reduction of replicative capacity of the viral polymerase. Therefore, our data suggest that the significant reduction in IAV replication by glycolytic interference occurs mainly due to an impairment of the dynamic regulation of the viral polymerase which conveys the transition of the enzyme’s function from transcription to replication. Author Summary: Upon infection the influenza A virus alters the metabolism of infected cells. Among others, this includes a pronounced increase in glucose metabolism. We aimed to get a better understanding of these metabolic virus-host interactions and to unravel the mechanism by which glycolytic inhibition impairs the viral life cycle. On the one hand, we observed a virus-induced upregulation of many glycolysis metabolites which could often be reversed by the administration of a glycolysis inhibitor. On the other hand, our data suggested that the inhibitor treatment severely impaired viral propagation by interfering with the regulation of the viral polymerase. This manifested in an extended phase of transcription, while replication was strongly reduced. Additionally, we assessed the safety and tolerability of the used drug in immortalized and primary cells. Our study sheds more light on metabolic virus-host interactions and provides a better understanding of metabolic interference as a potential host-targeted antiviral approach, which does not bear the risk of creating resistances.